Journal
What the Adverse Event Data Shows
455+ reports for semaglutide, 320+ for tirzepatide, with dosing errors recurring.
455+ reports for semaglutide, 320+ for tirzepatide, with dosing errors recurring. This piece sets out what is established on compounded semaglutide adverse events, which record holds it, and what remains unverified — with the underlying figures published as tables and charts so the reasoning is checkable rather than asserted.
Key findings
- 455+ reports for semaglutide, 320+ for tirzepatide, with dosing errors recurring.
- Every figure here is drawn from a dated capture or an FDA primary source.
- Regulatory framework and entity-specific claims are held to different evidence standards.
- Open fields render as explicit statuses, never as estimates.
- No provider pays for coverage or placement on this platform.
| Topic | compounded semaglutide adverse events |
|---|---|
| Category | Safety |
| Pricing captured | 2026-07-06 |
| Framework sources | FDA, verified 2026-07-23 |
| Provider relationship | No Public Evidence Found no financial relationship exists |
What the report counts do and do not show
More than 455 reports involving compounded semaglutide and more than 320 involving compounded tirzepatide as of early 2025, with dosing errors from multi-dose vials recurring and some cases requiring hospitalisation.
These are reports received, not confirmed causal findings, and reporting is voluntary and incomplete. They do not establish a comparative rate against approved products — no study has measured that.
The risks specific to compounding
Class effects — gastrointestinal reactions, the boxed warning on thyroid C-cell tumours, pancreatitis, gallbladder disease — apply to approved and compounded products alike, because they belong to the molecule.
The compounding-specific risks belong to the preparation. Concentration is set by the facility and not independently verified. Sterility assurance is the highest-consequence variable for an injectable and the hardest for a buyer to check. And identity: whether the active ingredient is the base form or a salt form FDA has said is inappropriate for compounding.
| Registered facility | Location | Last inspection | Form 483 | Action |
|---|---|---|---|---|
| Quva Pharma, Inc. | Sugar Land, TX | 2026-05-04 | No | Open — FDA has not determined whether further action will be taken |
| Empower Pharma | Houston, TX | 2025-11-14 | Yes | Open — FDA has not determined whether further action will be taken |
| Fresenius Kabi Compounding LLC dba Fagron St | Canton, MA | 2025-11-05 | Yes | Warning letter — Warning letter issued 12 May 2026 |
| AnazaoHealth Corporation | Las Vegas, NV | 2025-08-08 | Yes | Open — FDA has not determined whether further action will be taken |
| Fagron Compounding Services dba Fagron Steri | Wichita, KS | 2025-08-08 | Yes | Open — Regulatory meeting held 27 February 2026 |
| Olympia Pharmaceuticals | Orlando, FL | 2025-08-08 | Yes | Open — FDA has not determined whether further action will be taken |
| Quva Pharma, Inc. | Bloomsbury, NJ | 2025-04-04 | Yes | Open — FDA has not determined whether further action will be taken |
Presentation is a safety variable
An approved pen delivers a fixed dose with no measurement decision. A multi-dose vial reintroduces one, and dosing errors by a factor of ten have been documented where a patient or clinician drew the wrong volume.
FDA received more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide as of early 2025, with dosing errors recurring and some cases requiring hospitalisation. Those are reports received, not confirmed causal findings — but the failure mode is specific, avoidable, and a consequence of presentation.
Timeline data as a table
| March 2022 | Semaglutide (Wegovy) added to the FDA drug shortage list. |
|---|---|
| August 2022 | Ozempic (semaglutide) added to the shortage list. |
| December 2022 | Tirzepatide (Mounjaro, Zepbound) added to the shortage list. |
| 2 October 2024 | FDA declares the tirzepatide shortage resolved. |
| 19 December 2024 | FDA reaffirms resolution by declaratory order. |
| 18 February 2025 | 503A enforcement discretion for tirzepatide ends. |
| 21 February 2025 | FDA removes semaglutide injection from the shortage list. |
| 5 March 2025 | Court denies preliminary injunction, Outsourcing Facilities Association v. FDA. |
| 19 March 2025 | 503B enforcement discretion for tirzepatide ends. |
| 24 April 2025 | Court denies a further preliminary injunction. |
| 30 April 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. |
| 29 June 2026 | Comment docket on the bulks-list proposal closes. |
What the data does not establish?
No study has measured whether compounded preparations are more dangerous than approved ones in any quantified way. Adverse event reporting is voluntary and incomplete, and report counts are not rates.
The narrower claim the evidence does carry is that a specific avoidable error is occurring at meaningful volume. That is worth acting on without overstating it.
What would change this analysis?
Three things would. A final determination on the 503B bulks list proposal, which the closed docket now makes likely within months. A change in the approved-product pricing that has repriced the category — the $149 oral tier is recent and competitive pressure has been moving it. And any published pharmacokinetic work on compounded preparations, which would move several questions here from unmeasured to measured.
None of those is speculative. Each has a named decision-maker and, in two cases, a live process. This page carries its own date so the gap between what was checked and what is current stays visible.
How to check any of this yourself
Regulatory framework: FDA's compounding pages carry the statutory position and the declaratory orders that ended the shortage exception. Every framework claim on this platform links to one of them.
Facility status: FDA's registered outsourcing facility list is updated weekly and now publishes inspection dates, whether a Form 483 was issued, and the action status. State licensure sits with the relevant board of pharmacy — a different register, and the only one covering 503A pharmacies.
Pricing: every figure here is a dated capture against the provider's own published page, computed as a total. The full dataset is published as JSON and CSV so the arithmetic can be rerun.
Applying this to compounded semaglutide adverse events
455+ reports for semaglutide, 320+ for tirzepatide, with dosing errors recurring.
Everything above is checkable against a named public record. Where this platform has not performed that check, the field renders as an explicit status rather than an inferred value — which tells you precisely what to go and confirm.
What this means
- Regulatory framework and dates are cited to FDA primary sources.
- Pricing figures are dated captures against provider pages, computed as totals.
- Every open field carries an explicit status rather than an estimate.
What this does not mean
- That any named entity is compliant, safe, or non-compliant.
- That a lower price indicates better evidence or quality.
- That this platform certifies or endorses any facility or preparation.
- Pricing captured 2026-07-06; confirm at checkout before relying on it.
- Regulatory positions change through rulemaking, guidance and enforcement action.
- Entity-specific licence and enforcement records are covered on the monitoring pages, not here.
- Nothing here is legal or medical advice.
Frequently asked questions
What is the short answer on compounded semaglutide adverse events?
455+ reports for semaglutide, 320+ for tirzepatide, with dosing errors recurring.
Where do these figures come from?
Pricing from dated captures against provider pages (2026-07-06); regulatory facts from FDA primary sources.
Does any provider pay to appear here?
No. This platform has no affiliate, referral, sponsorship, or financial relationship with any provider.
How often is this updated?
When the underlying capture or regulatory position changes. Every page carries its own date.
Is this legal or medical advice?
No. It reports what named public records say on the dates they were checked. Clinical decisions belong with a prescriber and legal questions with a qualified adviser.
How can I check the figures myself?
The pricing dataset is published as JSON and CSV, the FDA register and inspection records are linked on every page that uses them, and each figure carries its capture date.
What if a record here is wrong?
Report it through the corrections process. Named entities can also respond through the right-to-respond route, and accepted corrections are logged with their date.
Sources
- GLP-1 pricing database
- FDA — Registered Outsourcing Facilities
- FDA — Information for Outsourcing Facilities
- FDA — Q&A: Outsourcing Facility Registration
Update history
| Date | Change |
|---|---|
| 2026-07-23 | Record published at current snapshot. |
Dates change only for substantive updates. Entities may submit a correction or response through the right-to-respond process.